Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids. Issue 4 (9th December 2019)

• Record Type: Journal Article
• Authors: Zhou, Xinyang; Wang, Shuhe; Zhu, Yuejie; Pan, Yufei; Zhang, Lihe; Yang, Zhenjun
• Is Part Of: Medicinal research reviews. Volume 40:Issue 4(2020)
• Page Start: 1178
• Page End: 1199
• Publication Date: 2019-12-09
• Subjects: delivery system -- lipophilic nucleoside -- nucleolipid; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21652
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: With the rapid development of synthetic technology and biological technology, many nucleic acid‐based drugs have entered the clinical trials. However, their inherent disabilities in actively and efficiently penetrating cell membranes still severely restrict their further application. The main drawback of cationic lipids, which have been widely used as nonviral vectors of nucleic acids, is their high cytotoxicity. A series of nucleoside‐based or nucleotide‐based nucleolipids have been reported in recent years, due to their oligonucleotide delivery capacity and low toxicity in comparison with cationic lipids. Lipophilic prodrugs of nucleoside analogs have extremely similar structures with nucleolipid vectors and are thus helpful for improving the transmembrane ability. This review introduces the progress of nucleolipids and provides new strategies for improving the delivery efficiency of nucleic acid‐based drugs, as well as lipophilic prodrugs of nucleosides or nucleotides for antiviral or anticancer therapies.